Inventor · disambiguated record
Oskar Smrzka
Also filed as: SMRZKA OSKAR
5 granted patents·13 pending applications·4 citations·filing 2015–2024
68Inventor score
Top patents by PatentIndex Score
18 records- 0176US2025051480A1Substances and methods for the use in prevention and/or treatment in huntington's diseaseHD IMMUNE GMBH·Filed 2024·Application pending·0 cites
- 0274US10053518B2Substances and methods for the use in prevention and/or treatment in Huntington's diseaseAFFIRIS AG·Filed 2015·Granted Aug 21, 2018·2 cites·9 claims
- 0370US10406197B2Substances and methods for the use in prevention and/or treatment in Huntington's diseaseAFFIRIS AG·Filed 2015·Granted Sep 10, 2019·2 cites·6 claims
- 0466US12065509B2Substances and methods for the use in prevention and/or treatment in huntingon's diseaseHD IMMUNE GMBH·Filed 2021·Granted Aug 20, 2024·0 cites·3 claims
- 0566US2021040236A1Substances and methods for the use in prevention and/or treatment in huntington's diseaseAFFIRIS AG·Filed 2020·Application pending·0 cites
- 0663US2024325560A1Compound for the sequestration of undesirable antibodies in a patientABLEVIA BIOTECH GMBH·Filed 2024·Application pending·0 cites
- 0760US2018327513A1Substances and methods for the use in prevention and/or treatment in huntington's diseaseAFFIRIS AG·Filed 2018·Application pending·0 cites
- 0854US11986536B2Compound for the sequestration of undesirable antibodies in a patientABLEVIA BIOTECH GMBH·Filed 2021·Granted May 21, 2024·0 cites·15 claims
- 0953US2025213707A1Compound for increasing efficacy of oncolytic virusesABLEVIA BIOTECH GMBH·Filed 2023·Application pending·0 cites
- 1045US2023355784A1Compound for the prevention or treatment of autoantibody-mediated conditionsABLEVIA BIOTECH GMBH·Filed 2021·Application pending·0 cites
- 1145US2023355660A1Compound for the sequestration of undesirable anti-peg antibodies in a patientABLEVIA BIOTECH GMBH·Filed 2021·Application pending·0 cites
- 1245US2023381334A1Compound for the sequestration of undesirable antibodies in a patientABLEVIA BIOTECH GMBH·Filed 2021·Application pending·0 cites
- 1345US2023355747A1Compound for increasing efficacy of viral vectorsABLEVIA BIOTECH GMBH·Filed 2021·Application pending·0 cites
- 1445US2023381328A1Compound for the prevention or treatment of myasthenia gravisABLEVIA BIOTECH GMBH·Filed 2021·Application pending·0 cites
- 1545US2023365655A1Compound for increasing the efficacy of factor viii replacement therapyABLEVIA BIOTECH GMBH·Filed 2021·Application pending·0 cites
- 1640US12011484B2Compound for the sequestration of undesirable antibodies in a patientABLEVIA BIOTECH GMBH·Filed 2020·Granted Jun 18, 2024·0 cites·10 claims
- 1733US2019127438A1Alpha chain of the high-affinity ige receptor (fceria)AFFIRIS AG·Filed 2017·Application pending·0 cites
- 1832US2018186896A1Vaccines for the treatment and prevention of ige mediated diseasesAFFIRIS AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Oskar Smrzka files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →